Antibiotic Commercial Models Under Revision To Tackle Stewardship Tension
Large pharma companies like AstraZeneca and GSK tout a project to devise new antibiotic development strategies that are independent of sales volumes, while some companies say stewardship and a sales-based system can go hand in hand.
You may also be interested in...
Both FDA and Congress are taking interest in combating antibiotic resistance, but FDA likely has more power to make headway in the near term, even as industry remains somewhat wary of that particular agenda item.
M&A can be expensive, but sometimes deals pay huge dividends. Bristol’s $2.1 billion acquisition of Medarex from 2009 looks like it’ll pay for itself many times over. Plus Actavis buys Warner Chilcott, Novo buys Xellia, and Elan and BTG each keep very busy.
Many VRBPAC committee members said they were impressed with Novavax’s booster data, including with its prototype vaccine, raising questions about whether non-mRNA vaccine platforms may be preferable to address COVID long-term.